Managed Financial Conflicts of Interest (FCOI) with Research Funded by the Public Health Service (PHS)

Current as of May 1, 2017

1.

Date Disclosed: April 22, 2013
Investigator with FCOI: William Federspiel, Ph.D.
Title: Professor of Chemical Engineering, Surgery and Bioengineering
PHS Funding: NIH 1 R0 1HL117637-01 Paracorporeal Ambulatory Assist Lung
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: ALung Technologies, Inc.
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh; consulting; reimbursed/sponsored travel; equity interest
Approximate dollar value of the SFI: Consulting income and reimbursed/sponsored travel between $20,000 – $39,000; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

2.

Date Disclosed: May 30, 2013
Investigator with FCOI: Angus Thomson, Ph.D., D.Sc.
Title: Distinguished Professor of Surgery and Immunology
PHS Funding: NIH 2 T32 AI074490-06 Interdisciplinary Training in Transplantation Biology
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

3.

Date Disclosed: May 30, 2013
Investigator with FCOI: Hideho Okada, M.D., Ph.D.
Title: Professor of Neurological Surgery, University of California, San Francisco
PHS Funding: 1 R01CA 174858-01 Peptide vaccine-based immunotherapy for children with recurrent ependymomas
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Stemline Therapeutics
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Stemline Therapeutics; consulting
Approximate dollar value of the SFI: Licensing proceeds from intellectual property rights between $10,000 - $19,999; consulting income between $5,000 - $9,999.

Date Disclosed: August 19, 2013
Investigator with FCOI: Bruce Freeman, Ph.D.
Title: Professor and Chair of Pharmacology and Chemical Biology
PHS Funding: NIH 4 R37 HL058115-17 Redox Transduction of Nitric Oxide Signaling
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: August 19, 2013
Investigator with FCOI: Francisco Schopfer, Ph.D.
Title: Research Associate Professor of Pharmacology and Chemical Biology
PHS Funding: NIH 4 R37 HL058115-17 Redox Transduction of Nitric Oxide Signaling
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Complexa, Inc.
Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

6. FCOI eliminated February 22, 2017

Date Disclosed: January 7, 2014
Investigator with FCOI: Yang Liu, Ph.D.
Title: Associate Professor of Medicine
PHS Funding: NIH 1 R01 EB016657-01 Novel Nanoscale Single-Cell Analysis of Exfoliative Cytology
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to NanoVision Diagnostics
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

7. **FCOI eliminated March 25, 2015**

**Date Disclosed:** January 30, 2014  
**Investigator with FCOI:** Robert W. Sobol, Ph.D.  
**Title:** Associate Professor of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 2 R44 ES021116-02 DNA Repair-on-a-Chip: Spatially Encoded Microwell Arrays  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Trevigen, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000-$19,999

8. **FCOI eliminated March 24, 2016**

**Date Disclosed:** February 11, 2014  
**Investigator with FCOI:** William Klunk, M.D., Ph.D.  
**Title:** Professor of Psychiatry and Neurology  
**PHS Funding:** NIH 5 U01 AG016976-15 National Alzheimer’s Coordinating Center (NACC)  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** GE Healthcare  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare; speaking honorarium  
**Approximate dollar value of the SFI:** $40,000 - $59,999

9.  

**Date Disclosed:** February 20, 2014  
**Investigator with FCOI:** Pawel Kalinski, M.D., Ph.D.  
**Title:** Professor of Surgery and Immunology  
**PHS Funding:** NIH 1 P50 CA159981-01 RPCI-UPCI Ovarian Cancer SPORE  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Not applicable  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to Pawel Kalinski  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

10. **FCOI eliminated March 24, 2016**

**Date Disclosed:** February 27, 2014  
**Investigator with FCOI:** William Klunk, M.D., Ph.D.  
**Title:** Professor of Psychiatry and Neurology
**PHS Funding:** NIH 5 P50 AG005133-30 (Sub-Project ID:  6967) *Natural History of Amyloid Deposition Familial Ad*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare

**Approximate dollar value of the SFI:** $40,000 - $59,999

---

11. *FCOI eliminated July 16, 2015*

**Date Disclosed:** April 4, 2014

**Investigator with FCOI:** Johnny Huard, Ph.D.

**Title:** Professor of Orthopaedic Surgery

**PHS Funding:** NIH 1 R21 EB016774-01A1 *Biomimetic Coacervate Delivery of Muscle Stem Cell to Improve Cardiac Repair*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Cook Myosite, Inc.

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Cook Myosite, Inc.; consulting

**Approximate dollar value of the SFI:** Consulting income between $5,000 – $9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

12. *FCOI eliminated February 22, 2017*

**Date Disclosed:** April 15, 2014

**Investigator with FCOI:** Randall Brand, M.D.

**Title:** Professor of Medicine

**PHS Funding:** NIH 5 R01 EB016657-02 *Novel Nanoscale Single-Cell Analysis of Exfoliative Cytology*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to NanoVision Diagnostics

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

13. *FCOI eliminated July 16, 2015*

**Date Disclosed:** May 5, 2014

**Investigator with FCOI:** Johnny Huard, Ph.D.

**Title:** Professor of Orthopaedic Surgery

**PHS Funding:** NIH 1 R21 AR066206-01 *The Use of Coacervate Technology as a New Drug Delivery System for Musculoskeletal Tissue*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Cook Myosite, Inc.
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Cook Myosite, Inc.; consulting

Approximate dollar value of the SFI: Consulting income between $5,000 – $9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

14.

Date Disclosed: May 9, 2014
Investigator with FCOI: Brad Dicianno, M.D.
Title: Associate Professor of Physical Medicine & Rehabilitation
PHS Funding: NIH 5 T35 AT005933-05 Student Research Training in Integrative, Complementary, and Alternative Medicine
Role on Research Project: Faculty Mentor
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to UbiCue, Inc.
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

15. FCOI eliminated July 16, 2015

Date Disclosed: May 14, 2014
Investigator with FCOI: Johnny Huard, Ph.D.
Title: Professor of Orthopaedic Surgery
PHS Funding: NIH 1 R01 AR065445-01 Bone Abnormalities & Healing Defect in Muscular Dystrophy
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Cook Myosite, Inc.
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Cook Myosite, Inc.; consulting
Approximate dollar value of the SFI: Consulting income between $5,000 – $9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

16.

Date Disclosed: May 20, 2014
Investigator with FCOI: Angus Thomson, Ph.D., D.Sc.
Title: Distinguished Professor of Surgery and Immunology
PHS Funding: NIH 5 U01 AI102456-02 Tomotherapy and Hematopoietic Stem Cells for Tolerance to Kidney Transplants
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

17. **FCOI eliminated June 11, 2015**

**Date Disclosed:** May 21, 2014  
**Investigator with FCOI:** Alexander Dömling, Ph.D.  
**Title:** Professor and Chair of Drug Design, University of Groningen  
**PHS Funding:** NIH 5 R01 GM097082-03 *ANCHOR: A PDB-Wide Real Time Discovery Resource of Novel PPI (Ant)-agonists*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Carmolex, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh, some of which has been sublicensed from Brainstage to Carmolex, Inc.; consulting; equity interest  
**Approximate dollar value of the SFI:** Consulting income between $10,000 – $19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

18.

**Date Disclosed:** May 27, 2014  
**Investigator with FCOI:** Angus Thomson, Ph.D., D.Sc.  
**Title:** Distinguished Professor of Surgery and Immunology  
**PHS Funding:** NIH 5 U01 AI051698-10 *Rhesus Monkey Dendritic Cells for Transplant Tolerance*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

19. **FCOI eliminated April 26, 2017**

**Date Disclosed:** May 27, 2014  
**Investigator with FCOI:** Saul Shiffman, Ph.D.  
**Title:** Professor of Psychology  
**PHS Funding:** NIH 1 R01 DA034629-01 *Cessation in Non-Daily Smokers: a RCT of NRT with Ecological Momentary Assessment*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** GlaxoSmithKline  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $20,000 – $39,999
20.

Date Disclosed: May 27, 2014  
Investigator with FCOI: Radhika Muzumdar, M.D.  
Title: Associate Professor of Pediatrics  
PHS Funding: NIH 7 R0 1AG035114-06 Novel Regulators of Glucose Homeostasis in Aging  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Albert Einstein College of Medicine  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the Albert Einstein College of Medicine and licensed to CohBar, Inc.  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

21. FCOI eliminated February 22, 2017

Date Disclosed: June 9, 2014  
Investigator with FCOI: Yang Liu, Ph.D.  
Title: Associate Professor of Medicine  
PHS Funding: NIH 1 R01 CA185363-01 (PQC2) Nanoscale Changes in 3D Nuclear Architecture During Breast Tumorigenesis  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to NanoVision Diagnostics  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

22.

Date Disclosed: July 3, 2014  
Investigator with FCOI: Joel S. Schuman, M.D.  
Title: Professor and Chair of Ophthalmology  
PHS Funding: NIH 1 T32 NS086749-01 Training in the Neurobiology of Neurological Disease  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Massachusetts Institute of Technology  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the Massachusetts Institute of Technology and licensed to Carl Zeiss Meditec, Inc.  
Approximate dollar value of the SFI: $1 - $4,999

23.

Date Disclosed: July 8, 2014  
Investigator with FCOI: Joel S. Greenberger, M.D.  
Title: Professor and Chair of Radiation Oncology
24.

Date Disclosed: July 8, 2014
Investigator with FCOI: Michael W. Epperly, Ph.D.
Title: Associate Professor of Radiation Oncology
PHS Funding: NIH 5 U19 AI068021-09 Mitochondrial Target for Radiation Mitigation
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

25.

Date Disclosed: July 21, 2014
Investigator with FCOI: Joel S. Schuman, M.D.
Title: Professor and Chair of Ophthalmology
PHS Funding: NIH 5 R01 EY013516-10 Advanced Imaging for Glaucoma
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Massachusetts Institute of Technology
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the Massachusetts Institute of Technology and licensed to Carl Zeiss Meditec, Inc.
Approximate dollar value of the SFI: $1 - $4,999

26.

Date Disclosed: July 24, 2014
Investigator with FCOI: William R. Wagner, Ph.D.
Title: Professor of Surgery
PHS Funding: NIH 5 R01 HL105911-04 Biodegradable, Thermoresponsive Hydrogels to Treat Ischemic Cardiomyopathy
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
27.

**Date Disclosed:** July 31, 2014  
**Investigator with FCOI:** Stephen H. Thorne, Ph.D.  
**Title:** Assistant Professor of Cell Biology  
**PHS Funding:** NIH 1 R01 CA178766-01A1 *Creation of Immuno-Oncolytic Viruses for Cancer Therapy*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Western Oncolytics  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Western Oncolytics; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

28.

**Date Disclosed:** August 19, 2014  
**Investigator with FCOI:** Bruce Freeman, Ph.D.  
**Title:** Professor and Chair of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 5 R01 AT006822-04 *Formation of Omega 3-Derived Electrophiles During Inflammation*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

29.

**Date Disclosed:** August 20, 2014  
**Investigator with FCOI:** Dario A. A. Vignali, Ph.D.  
**Title:** Professor and Vice Chair of Immunology  
**PHS Funding:** NIH 7 R01 AI091977-05 *A Regulatory Triad: IL35, Tregs and iTr35*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** St. Jude Children’s Research Hospital  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the St. Jude Children’s Research Hospital  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

30. **FCOI eliminated May 1, 2015**

**Date Disclosed:** September 22, 2014  
**Investigator with FCOI:** Johnny Huard, Ph.D.  
**Title:** Professor of Orthopaedic Surgery  
**PHS Funding:** NIH 5 P01 AG043376-02 *Cell Autonomous and Non-Autonomous Mechanisms of Aging*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Cook Myosite, Inc.
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Cook Myosite, Inc.; consulting
Approximate dollar value of the SFI: Consulting income between $5,000 – $9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

31. **FCOI eliminated February 24, 2016**

Date Disclosed: February 4, 2015
Investigator with FCOI: Gregory Kato, M.D.
Title: Professor of Medicine
PHS Funding: NIH 1 R01 HL121386-01A1 *Characterizing Mechanisms of Sickle Cell Crisis Via Dynamic Optical Assay*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Baxter
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $5,000 – $9,999

32.

Date Disclosed: February 5, 2015
Investigator with FCOI: Marjorie Skubic, Ph.D., University of Missouri-Columbia
Title: Professor of Electrical and Computer Engineering
PHS Funding: AHRQ 1 R01 HS022889-01A1 *Self-Management via Health Kiosk by Community-residing Older Adults*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Foresite Healthcare, LLC
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Missouri-Columbia and licensed to Foresite Healthcare, LLC; equity interest; advisor/board member
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

33.

Date Disclosed: February 17, 2015
Investigator with FCOI: Lee M. Ritterband, Ph.D.
Title: Professor of Psychiatry and Neurobehavioral Sciences, University of Virginia
PHS Funding: NIH 4 UH 3HL125103-01 *Pragmatic Trial of Behavioral Interventions for Insomnia in Hypertensive Patients*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: BeHealth Solutions, LLC
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Virginia and licensed to BeHealth Solutions, LLC; equity interest

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

34.

**Date Disclosed:** March 20, 2015  
**Investigator with FCOI:** Mark H. Yazer, M.D.  
**Title:** Professor of Pathology  
**PHS Funding:** NIH HHSN 268201100004 *Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Octapharma  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $5,000 – $9,999

35.

**Date Disclosed:** April 7, 2015  
**Investigator with FCOI:** Michael J. Palladino, PhD  
**Title:** Professor of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1R01GM108073-01A1 *Pre-clinical Studies of Novel Mitochondrial Gene Therapies*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

36. *FCOI eliminated May 10, 2016*

**Date Disclosed:** April 15, 2015  
**Investigator with FCOI:** Michael J. Caterina, M.D., Ph.D.  
**Title:** Professor of Neurosurgery, Biological Chemistry and Neuroscience, Johns Hopkins University  
**PHS Funding:** NIH 5 R37DK054824-15 *Nitric Oxide in Bladder Neural-Epithelial Signaling*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Johns Hopkins University  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the Johns Hopkins University and licensed to Merck  
**Approximate dollar value of the SFI:** $40,000 - $59,999
37. FCOI eliminated December 29, 2015

Date Disclosed: April 29, 2015  
Investigator with FCOI: Mary Rothstein  
Title: Research Specialist, University of Pittsburgh Cancer Institute  
PHS Funding: HHSN 261201400043C Failed Tubulin Inhibitor Reformulated as Localized Adjuvant Therapy for Head and Neck Cancer  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Qrono, Inc.  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Qrono, Inc.; equity interest  
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

38.  
Date Disclosed: April 30, 2015  
Investigator with FCOI: Louis D. Falo, Jr., M.D., Ph.D.  
Title: Professor and Chair of Dermatology  
PHS Funding: 5 P50 CA121973-07 (Sub-project ID: 7388) SPORE in Skin Cancer  
Role on Research Project: Principal Investigator of bench, and Co-Investigator on human subject, research  
Name of Entity in which Significant Financial Interest (SFI) is held: SkinJect  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SkinJect; equity interest  
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

39.  
Date Disclosed: April 30, 2015  
Investigator with FCOI: Louis D. Falo, Jr., M.D., Ph.D.  
Title: Professor and Chair of Dermatology  
PHS Funding: 5 R01 EB012776-04 Fabrication and Characterization of Dissolvable Microneedle Arrays  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: SkinJect  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SkinJect; equity interest  
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
40. **FCOI eliminated March 24, 2016**

**Date Disclosed:** May 5, 2015  
**Investigator with FCOI:** Chester Mathis, Ph.D.  
**Title:** Professor of Radiology  
**PHS Funding:** 3 U01 AG024904-10 Alzheimer’s Disease Neuroimaging Initiative  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare  
**Approximate dollar value of the SFI:** $20,000 - $39,999

41.  

**Date Disclosed:** May 14, 2015  
**Investigator with FCOI:** Saul Shiffman, Ph.D.  
**Title:** Professor of Psychology  
**PHS Funding:** NIH 5 R01 DA034629-02 Cessation in Non-Daily Smokers: a RCT of NRT with Ecological Momentary Assessment  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Niconovum (a subsidiary of Reynolds American, Inc.); JSR, LLC  
**Nature of the SFI:** Consulting with Niconovum; intellectual property rights (e.g., royalties, patents, copyrights) assigned to JSR; equity interest in JSR  
**Approximate dollar value of the SFI:** Consulting income between $80,000 – $99,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

42. **FCOI eliminated March 24, 2016**

**Date Disclosed:** May 27, 2015  
**Investigator with FCOI:** Chester Mathis, Ph.D.  
**Title:** Professor of Radiology  
**PHS Funding:** NIH 5 P50 AG005133-30 (Sub-Project ID: 6967) Natural History of Amyloid Deposition Familial Ad  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare  
**Approximate dollar value of the SFI:** $20,000 - $39,999
43.

Date Disclosed: May 28, 2015
Investigator with FCOI: Steven Woodcock, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R01 AT006822 Formation of omega 3-derived electrophiles during inflammation
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

44.

Date Disclosed: May 28, 2015
Investigator with FCOI: Steven Woodcock, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R37 HL058115 Redox transduction of nitric oxide signaling
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

45.

Date Disclosed: May 28, 2015
Investigator with FCOI: Chen-Shan (Julia) Woodcock, M.S.
Title: Graduate Student Researcher, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R37 HL058115 Redox transduction of nitric oxide signaling
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

46.

Date Disclosed: May 28, 2015
Investigator with FCOI: Chen-Shan (Julia) Woodcock, M.S.
Title: Graduate Student Researcher, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R01 HL064937 Redox-Derived Pulmonary Anti-Inflammatory Mediators
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999
Date Disclosed: May 28, 2015  
Investigator with FCOI: Dario Vitturi, Ph.D.  
Title: Research Instructor, Department of Pharmacology & Chemical Biology  
PHS Funding: NIH R01 HL064937 Redox-Derived Pulmonary Anti-Inflammatory Mediators  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

Date Disclosed: May 28, 2015  
Investigator with FCOI: Dario Vitturi, Ph.D.  
Title: Research Instructor, Department of Pharmacology & Chemical Biology  
PHS Funding: NIH R01 AT006822 Formation of omega 3-derived electrophiles during inflammation  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

Date Disclosed: May 28, 2015  
Investigator with FCOI: Dario Vitturi, Ph.D.  
Title: Research Instructor, Department of Pharmacology & Chemical Biology  
PHS Funding: NIH R37 HL058115 Redox transduction of nitric oxide signaling  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

FCOI eliminated April 26, 2017

Date Disclosed: June 23, 2015  
Investigator with FCOI: Brian Suffoletto, M.D.  
Title: Assistant Professor of Emergency Medicine  
PHS Funding: NIH 5 K23 AA023284-02 A Text-Message Intervention to Reduce Alcohol Use Among Young Adult ED Patients  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to healthStratica  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
51.

Date Disclosed: July 31, 2015
Investigator with FCOI: Brian Suffoletto, M.D.
Title: Assistant Professor of Emergency Medicine
PHS Funding: NIH R34 AA023047 Brief Alcohol Screening and Intervention for Community College Students (BASICCS)
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to healthStratica
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

52.

Date Disclosed: August 11, 2015
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.
Title: Research Assistant Professor of Pharmacology & Chemical Biology
PHS Funding: NIH R01 HL064937 Redox-Derived Pulmonary Anti-Inflammatory Mediators
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

53.

Date Disclosed: August 11, 2015
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.
Title: Research Assistant Professor of Pharmacology & Chemical Biology
PHS Funding: NIH P01 HL103455 Vascular Subphenotypes of Lung Disease
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

54.

Date Disclosed: August 11, 2015
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.
Title: Research Assistant Professor of Pharmacology & Chemical Biology
PHS Funding: NIH R01 AT006822 Formation of omega 3-derived electrophiles during inflammation
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999
55.

Date Disclosed: August 11, 2015  
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.  
Title: Research Assistant Professor of Pharmacology & Chemical Biology  
PHS Funding: NIH R01 DK071085 Roles of Nitric Oxide and Superoxide in Cystitis  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

56.

Date Disclosed: August 11, 2015  
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.  
Title: Research Assistant Professor of Pharmacology & Chemical Biology  
PHS Funding: NIH R37 HL058115 Redox transduction of nitric oxide signaling  
Role on Research Project: Principal Investigator of animal, and Co-Investigator of bench and human subject, research  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

57. FCOI eliminated September 1, 2016

Date Disclosed: August 11, 2015  
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.  
Title: Research Assistant Professor of Pharmacology & Chemical Biology  
PHS Funding: NIH 5 TL1 TR000145-10 University of Pittsburgh Clinical and Translational Science Institute  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

58.

Date Disclosed: August 13, 2015  
Investigator with FCOI: Francisco Schopfer, Ph.D.  
Title: Research Associate Professor of Pharmacology and Chemical Biology  
PHS Funding: NIH 1 R01 AR066548-01A1 The Immunoregulatory Effects of Electrophilic Fatty acids on Psoriasis  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Complexa, Inc.

Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

59.

Date Disclosed: August 18, 2015
Investigator with FCOI: Mark Gladwin, M.D.
Title: Professor and Chair of Medicine
PHS Funding: NIH 1 K23 HL124051-01A1 Nitrite Modulation of Hypertension, Platelet Activation and Mitochondrial Function
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: National Institutes of Health
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the National Institutes of Health and licensed to MAST Therapeutics
Approximate dollar value of the SFI: $1 - $4,999

60. FCOI eliminated March 24, 2016

Date Disclosed: October 1, 2015
Investigator with FCOI: Chester Mathis, Ph.D.
Title: Professor of Radiology
PHS Funding: NIH 1 K23 AG049945-01A1 The Aging Brain and the Cognition-Mobility Interface in Clinically Normal Older Adults
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare
Approximate dollar value of the SFI: $20,000 - $39,999

61. FCOI eliminated March 24, 2016

Date Disclosed: October 1, 2015
Investigator with FCOI: William Klunk, M.D., Ph.D.
Title: Professor of Psychiatry and Neurology
PHS Funding: NIH 1 K23 AG049945-01A1 The Aging Brain and the Cognition-Mobility Interface in Clinically Normal Older Adults
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare
Approximate dollar value of the SFI: $20,000 - $39,999
62. **FCOI eliminated August 25, 2016**

**Date Disclosed:** February 3, 2016  
**Investigator with FCOI:** Fuchiang (Rich) Tsui, Ph.D.  
**Title:** Research Assistant Professor of Biomedical Informatics  
**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Vervtality  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

63. **FCOI eliminated April 26, 2017**

**Date Disclosed:** February 8, 2016  
**Investigator with FCOI:** James Eles  
**Title:** Graduate Student, Department of Bioengineering  
**PHS Funding:** NIH R01 NS062019 *Biomimetic Surfaces for Neural Implants*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

64. **FCOI eliminated April 26, 2017**

**Date Disclosed:** February 8, 2016  
**Investigator with FCOI:** Xinyan (Tracy) Cui  
**Title:** Professor of Bioengineering  
**PHS Funding:** NIH R01 NS062019 *Biomimetic Surfaces for Neural Implants*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

65.

**Date Disclosed:** February 12, 2016  
**Investigator with FCOI:** Edward Prochownik, M.D., Ph.D.  
**Title:** Professor of Pediatrics and Microbiology & Molecular Genetics
PHS Funding: NIH 1 U54 CA199092-01 Center for Multiple Myeloma Nanotherapy
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

66.

Date Disclosed: February 22, 2016
Investigator with FCOI: Andrew Hinck, Ph.D.
Title: Visiting Professor of Structural Biology
PHS Funding: NIH R01 CA172886 Inhibition of the Tumor-Promoting Effects of TGF-Beta in Advanced Prostate Cancer
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Texas Health Science Center at San Antonio
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Texas Health Science Center at San Antonio
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

67.

Date Disclosed: April 25, 2016
Investigator with FCOI: Rebecca Jacobson, M.D., M.S.
Title: Professor of Biomedical Informatics and Pathology
PHS Funding: NIH U24 CA180921 Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: NEXI
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

68.

Date Disclosed: April 25, 2016
Investigator with FCOI: Girish Chavan
Title: Staff, Department of Biomedical Informatics
PHS Funding: NIH U24 CA180921 Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: NEXI
Nature of the SFI: Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: April 25, 2016
Investigator with FCOI: Eugene Tseytlin
Title: Staff, Department of Biomedical Informatics
PHS Funding: NIH U24 CA180921 Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: NEXI
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: May 16, 2016
Investigator with FCOI: Dario Vitturi, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology
PHS Funding: NIH U01 HL117721 Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

Date Disclosed: June 9, 2016
Investigator with FCOI: Joseph Glorioso, Ph.D.
Title: Professor, Department of Microbiology & Molecular Genetics
PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus
**Approximate dollar value of the SFI:** Consulting income between $100,000 - $149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

72.

**Date Disclosed:** June 9, 2016  
**Investigator with FCOI:** Paola Grandi, Ph.D.  
**Title:** Assistant Professor, Department of Neurological Surgery  
**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus  
**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus  
**Approximate dollar value of the SFI:** Consulting income between $100,000 - $149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

73.

**Date Disclosed:** June 9, 2016  
**Investigator with FCOI:** Justus Cohen, Ph.D.  
**Title:** Research Instructor, Department of Microbiology & Molecular Genetics  
**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

74.

**Date Disclosed:** June 9, 2016  
**Investigator with FCOI:** William Goins, Ph.D.  
**Title:** Research Assistant Professor, Department of Microbiology & Molecular Genetics  
**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus  
**Nature of the SFI:** Consulting; equity interest  
**Approximate dollar value of the SFI:** Consulting income between $20,000 - $39,999; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
75.

Date Disclosed: June 9, 2016
Investigator with FCOI: Nduka Amankulor, M.D.
Title: Assistant Professor, Department of Neurological Surgery
PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $5,000 - $9,999

76.

Date Disclosed: June 13, 2016
Investigator with FCOI: Paola Grandi, Ph.D.
Title: Assistant Professor, Department of Neurological Surgery
PHS Funding: NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus
Approximate dollar value of the SFI: Consulting income between $100,000 - $149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

77.

Date Disclosed: June 13, 2016
Investigator with FCOI: William Goins, Ph.D.
Title: Research Assistant Professor, Department of Microbiology & Molecular Genetics
PHS Funding: NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting; equity interest
Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

78.

Date Disclosed: June 13, 2016
Investigator with FCOI: Nduka Amankulor, M.D.
Title: Assistant Professor, Department of Neurological Surgery
PHS Funding: NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus
Approximate dollar value of the SFI: Consulting income between $5,000 - $9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

79. FCOI eliminated October 3, 2016

Date Disclosed: June 28, 2016
Investigator with FCOI: Michael McClincy, M.D.
Title: Fellow, Massachusetts General Hospital
PHS Funding: NIH 5 TL1 TR000145-10 University of Pittsburgh Clinical and Translational Science Institute
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

80.

Date Disclosed: June 28, 2016
Investigator with FCOI: Kevin Bell, Ph.D.
Title: Research Assistant Professor, Department of Orthopaedic Surgery
PHS Funding: NIH 5 TL1 TR000145-10 University of Pittsburgh Clinical and Translational Science Institute
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

81. FCOI eliminated August 25, 2016

Date Disclosed: June 28, 2016
Investigator with FCOI: Robert Hartman, Ph.D.
Title: Postdoctoral Associate, Department of Physical Medicine & Rehabilitation
PHS Funding: NIH 5 TL1 TR000145-10 University of Pittsburgh Clinical and Translational Science Institute
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

82.

Date Disclosed: June 28, 2016  
Investigator with FCOI: Xinyan (Tracy) Cui  
Title: Professor of Bioengineering  
PHS Funding: NIH 5 TL1 TR000145-10 University of Pittsburgh Clinical and Translational Science Institute  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

83. FCOI eliminated September 2, 2016

Date Disclosed: June 28, 2016  
Investigator with FCOI: James Eles  
Title: Graduate Student, Department of Bioengineering  
PHS Funding: NIH 5 TL1 TR000145-10 University of Pittsburgh Clinical and Translational Science Institute  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

84.

Date Disclosed: July 1, 2016  
Investigator with FCOI: Joel S. Greenberger, M.D.  
Title: Professor and Chair of Radiation Oncology  
PHS Funding: NIH 2 U19 AI068021-11 Signature-Directed, Sequential Delivery of Radiation Mitigators  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
**Date Disclosed:** July 1, 2016  
**Investigator with FCOI:** Michael W. Epperly, Ph.D.  
**Title:** Associate Professor of Radiation Oncology  
**PHS Funding:** NIH 2 U19 AI068021-11 *Signature-Directed, Sequential Delivery of Radiation Mitigators*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed:** July 5, 2016  
**Investigator with FCOI:** Shivalingappa Swamynathan, Ph.D.  
**Title:** Associate Professor of Ophthalmology and Cell Biology  
**PHS Funding:** NIH 5 R01 EY022898-03 *Corneal Expression and Function of Slurp1*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed:** July 5, 2016  
**Investigator with FCOI:** Sudha Swamynathan  
**Title:** Research Technician, Department of Ophthalmology  
**PHS Funding:** NIH 5 R01 EY022898-03 *Corneal Expression and Function of Slurp1*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed:** July 13, 2016  
**Investigator with FCOI:** Yuri Nikiforov, M.D., Ph.D.  
**Title:** Professor of Pathology  
**PHS Funding:** NIH 2 P50 CA097190-11 *Head and Neck Cancer SPORE*
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to UPMC  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

89.

**Date Disclosed:** July 14, 2016  
**Investigator with FCOI:** Bruce Freeman, Ph.D.  
**Title:** Professor and Chair of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 1 R21 AI122071-01A1 *The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

90.

**Date Disclosed:** July 14, 2016  
**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.  
**Title:** Research Assistant Professor of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1 R21 Al122071-01A1 *The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology*  
**Role on Research Project:** Principal Investigator of bench, and Co-Investigator on human subject, research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999

91.

**Date Disclosed:** August 9, 2016  
**Investigator with FCOI:** Dario A. A. Vignali, Ph.D.  
**Title:** Professor and Vice Chair of Immunology  
**PHS Funding:** NIH 9 R01 CA203689-07A1 *Interleukin-35 and the Tumor Microenvironment*  
**Role on Research Project:** Principal Investigator of bench, and Co-Investigator on non-bench, research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Tizona Therapeutics  
**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the St. Jude Children’s Research Hospital and licensed to Tizona Therapeutics;
**Approximate dollar value of the SFI:** Consulting income between $80,000 - $99,999; licensing proceeds from intellectual property rights between $40,000 - $59,999; equity interest is SFI whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

92.

**Date Disclosed:** August 23, 2016  
**Investigator with FCOI:** Bruce Freeman, Ph.D.  
**Title:** Professor and Chair of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 1 K01 HL133331-01 Protection against sickle cell disease nephropathy by nitrated fatty acids  
**Role on Research Project:** Primary Mentor  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

93.

**Date Disclosed:** August 23, 2016  
**Investigator with FCOI:** Dario Vitturi, Ph.D.  
**Title:** Research Instructor, Department of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1 K01 HL133331-01 Protection against sickle cell disease nephropathy by nitrated fatty acids  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999

94.

**Date Disclosed:** August 23, 2016  
**Investigator with FCOI:** Francisco Schopfer, Ph.D.  
**Title:** Research Associate Professor of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 1 K01 HL133331-01 Protection against sickle cell disease nephropathy by nitrated fatty acids  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting; equity interest; Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.
**Approximate dollar value of the SFI:** Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

95.

**Date Disclosed:** September 1, 2016  
**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.  
**Title:** Research Assistant Professor of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*  
**Role on Research Project:** Principal Investigator of animal, and Co-Investigator of bench and human subject, research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999

96.

**Date Disclosed:** September 1, 2016  
**Investigator with FCOI:** Bruce Freeman, Ph.D.  
**Title:** Professor and Chair of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*  
**Role on Research Project:** Principal Investigator of bench, and Co-Investigator on human subject, research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

97.

**Date Disclosed:** September 1, 2016  
**Investigator with FCOI:** Steven Woodcock, Ph.D.  
**Title:** Research Instructor, Department of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999
98.

Date Disclosed: September 19, 2016  
Investigator with FCOI: Mark Gladwin, M.D.  
Title: Professor and Chair of Medicine  
PHS Funding: NIH 2 P01 HL103455-06 Therapeutic Targeting of Vascular Subphenotypes of Lung Disease  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: National Institutes of Health  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the National Institutes of Health and licensed to MAST Therapeutics  
Approximate dollar value of the SFI: $1 - $4,999

99.

Date Disclosed: September 19, 2016  
Investigator with FCOI: Bruce Freeman, Ph.D.  
Title: Professor and Chair of Pharmacology and Chemical Biology  
PHS Funding: NIH 2 P01 HL103455-06 Therapeutic Targeting of Vascular Subphenotypes of Lung Disease  
Role on Research Project: Principal Investigator of bench, and Co-Investigator on human subject, research  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

100.

Date Disclosed: September 19, 2016  
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.  
Title: Research Assistant Professor of Pharmacology & Chemical Biology  
PHS Funding: NIH 2 P01 HL103455-06 Therapeutic Targeting of Vascular Subphenotypes of Lung Disease  
Role on Research Project: Principal Investigator of animal, and Co-Investigator of bench and human subject, research  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

101.

Date Disclosed: September 19, 2016  
Investigator with FCOI: Steven Woodcock, Ph.D.  
Title: Research Instructor, Department of Pharmacology & Chemical Biology  
PHS Funding: NIH 2 P01 HL103455-06 Therapeutic Targeting of Vascular Subphenotypes of Lung Disease
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

Date Disclosed: September 23, 2016
Investigator with FCOI: Matthew Neal, M.D.
Title: Assistant Professor of Surgery and Critical Care Medicine
PHS Funding: NIH 1 R35 GM119526-01 Mechanistic Elucidation and Targeted Therapy of Platelet Dysfunction After Trauma
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

FCOI eliminated March 29, 2017

Date Disclosed: September 23, 2016
Investigator with FCOI: Brian Suffoletto, M.D.
Title: Assistant Professor of Emergency Medicine
PHS Funding: NIH 1 R01 AA23650-01A1 Mechanisms of Change for an Effective Alcohol Text Message Intervention
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to healthStratica
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: September 27, 2016
Investigator with FCOI: Patricia Opresko, Ph.D.
Title: Associate Professor of Environmental and Occupational Health
PHS Funding: NIH 2 R44 GM108187-03 GammaPNA Miniprobes for Telomere Analysis and RNA FISH
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to PNA Innovations, Inc.
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Date Disclosed: October 5, 2016  
**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.  
**Title:** Research Assistant Professor of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1 U54 DK112079-01 *University of Pittsburgh O'Brien Cooperative Research Center Program*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999

Date Disclosed: October 10, 2016  
**Investigator with FCOI:** Guergana Savova, Ph.D.  
**Title:** Associate Professor of Pediatrics, Harvard Medical School and Computational Health Informatics Program at Boston Children’s Hospital  
**PHS Funding:** NIH 5 U24 CA184407-03 *Cancer Deep Phenotype Extraction from Electronic Medical Records*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Wired Informatics, LLC  
**Nature of the SFI:** Equity interest  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: October 18, 2016  
**Investigator with FCOI:** John Kellum, M.D.  
**Title:** Professor and Vice Chair for Research, Department of Critical Care Medicine  
**PHS Funding:** NIH 1 R01 DK106256-01A1 *Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Astute Medical  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999

Date Disclosed: October 25, 2016  
**Investigator with FCOI:** Alexander Deiters, Ph.D.  
**Title:** Professor of Chemistry
**PHS Funding:** NIH 1 R21 HD 85206-01A1 *Optical Control of Translation and Gene Editing in Zebrafish Embryos*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** North Carolina State University

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to North Carolina State University

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed:** October 26, 2016

**Investigator with FCOI:** Bonnie Hall, Ph.D.

**Title:** Research Instructor, Department of Microbiology & Molecular Genetics

**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** $10,000 - $19,999

---

**Date Disclosed:** November 2, 2016

**Investigator with FCOI:** Mary Loghmani, P.T., Ph.D.

**Title:** Associate Professor of Physical Therapy, Indiana University

**PHS Funding:** NIH 5 P2C HD086843-02 *Alliance for Regenerative Rehabilitation Research & Training (AR3T)*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Health Smart Technologies, Inc.

**Nature of the SFI:** Equity interest

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed:** November 17, 2016

**Investigator with FCOI:** Maliha Zahid, M.D., Ph.D.

**Title:** Research Instructor, Department of Developmental Biology

**PHS Funding:** NIH 1 UL1 TR 001857-01 *University of Pittsburgh Clinical and Translational Science Institute*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

112.

Date Disclosed: January 4, 2017  
Investigator with FCOI: Lee M. Ritterband, Ph.D.  
Title: Professor of Psychiatry and Neurobehavioral Sciences, University of Virginia  
PHS Funding: NIH 1 R03 HL135213-01 Feasibility and Acceptability of an internet-based cognitive-behavioral treatment for insomnia in adults with asthma  
Role on Research Project: Consultant  
Name of Entity in which Significant Financial Interest (SFI) is held: BeHealth Solutions, LLC  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Virginia and licensed to BeHealth Solutions, LLC; equity interest  
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

113.

Date Disclosed: January 17, 2017  
Investigator with FCOI: Yadong Wang, Ph.D.  
Title: Professor, Department of Bioengineering  
PHS Funding: NIH 7 R21 EB016774-03 Biomimetic Coacervate Delivery of Muscle Stem Cell to Improve Cardiac Repair  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

114.

Date Disclosed: March 2, 2017  
Investigator with FCOI: Kenneth W. Kinzler, PhD  
Title: Professor of Oncology, Johns Hopkins University  
PHS Funding: NIH 2 U01 CA152753-06 ctDNA for the Early Detection and Monitoring of Colorectal Cancer  
Role on Research Project: Principal Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Sysmex Corporation  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University and licensed to Sysmex Corporation; payment for services  
Approximate dollar value of the SFI: Intellectual property royalty distributions between $60,000-$79,999; payment for services between $60,000-$79,999